share_log

Short Interest in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Expands By 26.1%

Short Interest in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Expands By 26.1%

阿瓦洛治療公司(空頭股數市場代碼：AVTX)的業務增長26.1%
Defense World ·  2022/10/01 03:31

Avalo Therapeutics, Inc. (NASDAQ:AVTX – Get Rating) was the recipient of a significant growth in short interest in the month of September. As of September 15th, there was short interest totalling 66,600 shares, a growth of 26.1% from the August 31st total of 52,800 shares. Currently, 0.8% of the company's shares are short sold. Based on an average daily trading volume, of 52,000 shares, the days-to-cover ratio is currently 1.3 days.

阿瓦洛治療公司(納斯達克代碼：AVTX-GET評級)是9月份空頭股數業務大幅增長的接受者。截至9月15日，空頭股數共有66,600股，比8月31日的52,800股增長26.1%。目前，該公司0.8%的股票被賣空。以日均成交量52,000股計算，目前天數與回補比率為1.3天。

Avalo Therapeutics Stock Down 0.3 %

Avalo治療公司股價下跌0.3%

Shares of Avalo Therapeutics stock opened at $3.32 on Friday. Avalo Therapeutics has a 1 year low of $2.42 and a 1 year high of $29.40. The business has a 50-day moving average of $4.36 and a two-hundred day moving average of $5.74. The company has a debt-to-equity ratio of 5.23, a quick ratio of 0.97 and a current ratio of 0.98.

週五，Avalo治療公司的股票開盤報3.32美元。Avalo Treateutics的一年低點為2.42美元，一年高位為29.40美元。該業務的50日移動均線切入位在4.36美元，200日移動均線切入位在5.74美元。該公司的負債權益比率為5.23，速動比率為0.97，流動比率為0.98。

Get
到達
Avalo Therapeutics
阿瓦洛治療公司
alerts:
警報：

Avalo Therapeutics (NASDAQ:AVTX – Get Rating) last announced its quarterly earnings results on Thursday, August 4th. The company reported ($1.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.80) by $0.42. Avalo Therapeutics had a negative return on equity of 449.27% and a negative net margin of 1,896.95%. The company had revenue of $1.03 million during the quarter. Analysts anticipate that Avalo Therapeutics will post -2.79 EPS for the current year.

阿瓦洛治療公司(納斯達克代碼：AVTX-GET評級)上一次公佈季度收益是在8月4日星期四。該公司公佈了本季度每股收益(EPS)(1.38美元)，比普遍預期的(1.80美元)高出0.42美元。阿瓦洛治療公司的淨資產回報率為負449.27%，淨利潤率為負1896.95%。該公司本季度營收為103萬美元。分析師預計，阿瓦洛治療公司本年度的每股收益將達到2.79美元。

Institutional Inflows and Outflows

機構資金流入和流出

A number of hedge funds have recently modified their holdings of the company. Stonepine Capital Management LLC grew its holdings in shares of Avalo Therapeutics by 77.7% during the fourth quarter. Stonepine Capital Management LLC now owns 1,510,095 shares of the company's stock worth $2,567,000 after buying an additional 660,095 shares in the last quarter. Millennium Management LLC bought a new position in shares of Avalo Therapeutics during the second quarter worth about $506,000. Goldman Sachs Group Inc. grew its holdings in shares of Avalo Therapeutics by 23.8% during the second quarter. Goldman Sachs Group Inc. now owns 649,653 shares of the company's stock worth $324,000 after buying an additional 124,769 shares in the last quarter. Northern Trust Corp grew its holdings in shares of Avalo Therapeutics by 3.1% during the fourth quarter. Northern Trust Corp now owns 533,578 shares of the company's stock worth $907,000 after buying an additional 16,276 shares in the last quarter. Finally, Renaissance Technologies LLC grew its stake in Avalo Therapeutics by 819.1% in the first quarter. Renaissance Technologies LLC now owns 367,193 shares of the company's stock valued at $266,000 after purchasing an additional 327,241 shares in the last quarter.
多家對衝基金最近調整了對該公司的持股。Stonepine Capital Management LLC在第四季度持有的Avalo Treateutics股票增加了77.7%。Stonepine Capital Management LLC現在擁有1,510,095股該公司股票，價值2,567,000美元，上個季度又購買了660,095股。Millennium Management LLC在第二季度購買了價值約506,000美元的Avalo治療公司股票的新頭寸。高盛股份有限公司在第二季度增持了阿瓦洛治療公司的股票23.8%。高盛股份有限公司現在持有該公司649,653股股票，價值324,000美元，該公司在上個季度又購買了124,769股。北方信託公司在第四季度增持了Avalo Treateutics的股票3.1%。Northern Trust Corp目前持有535,578股該公司股票，價值90.7萬美元，此前該公司在上個季度又購買了16,276股。最後，復興科技有限責任公司在第一季度將其在阿瓦洛治療公司的股份增加了819.1%。復興科技有限責任公司現在擁有367,193股該公司股票，價值266,000美元，在上個季度又購買了327,241股。

Analyst Ratings Changes

分析師評級發生變化

Separately, Royal Bank of Canada cut their target price on Avalo Therapeutics from $24.00 to $21.00 in a research note on Monday, July 11th.

另外，加拿大皇家銀行在7月11日星期一的一份研究報告中將阿瓦洛治療公司的目標價從24美元下調至21美元。

Avalo Therapeutics Company Profile

Avalo治療公司簡介

(Get Rating)

(獲取評級)

Avalo Therapeutics, Inc, a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome.

Avalo Treateutics，Inc.是一家臨牀階段的精密藥物公司，為免疫學、免疫腫瘤學和罕見遺傳病方面未得到滿足的臨牀需求的患者發現、開發和商業化靶向療法。該公司開發了AVTX-002，這是一種完全人類抗光的單抗，正在進行第二階段臨牀試驗，用於治療非嗜酸性哮喘以及炎症性腸道疾病，包括中到重度克羅恩病和潰瘍性結腸炎；以及第三階段臨牀試驗，用於治療新冠肺炎急性呼吸窘迫綜合徵。

Featured Stories

專題報道

  • Get a free copy of the StockNews.com research report on Avalo Therapeutics (AVTX)
  • EV Battery Maker Freyr Set For Major Global Expansion
  • MarketBeat: Week in Review 9/26 – 9/30
  • This Is A Memorable Time To Buy Into Micron Technology
  • Let Paychex Stock Work Hard For You
  • How Does Keurig Dr Pepper Compare To Larger Rivals Coke & Pepsi?
  • 免費獲取StockNews.com關於Avalo治療公司(AVTX)的研究報告
  • 電動汽車電池製造商Freyr將在全球大舉擴張
  • MarketBeat：回顧一週9/26-9/30
  • 這是買入美光科技的難忘時刻
  • 讓Paychex股票為您努力工作
  • Keurig Dr Pepper與規模更大的競爭對手可口可樂(Coke&Pepsi)相比如何？

Receive News & Ratings for Avalo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

接受《阿瓦洛治療日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Avalo治療公司和相關公司的最新新聞和分析師評級的每日簡要摘要。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論